Compare AdaptHealth Corp (AHCO) vs Aterian Inc (ATER) Price & Performance

AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.

The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.

Aterian (ATER) trades at $1.24, down 3.12% today, with a bullish technical signal from moving averages. The company shows improving operational trends with three consecutive quarterly earnings beats, though it remains unprofitable with a -30.78% net margin. Recent news highlights a special stockholders meeting on July 10, 2026, to vote on proposals that could return $0.85–$1.14 per share.

Investment outlook is mixed: positive technical momentum and potential shareholder returns contrast with persistent losses and negative cash flow. Key risks include sustained unprofitability and high short interest growth of 57.7% in March 2026. Analysts are evenly split between Buy and Hold ratings, reflecting cautious optimism amid fundamental challenges.